The present invention provides a novel carbamazepine hydrazide compound suitable for covalent attachment to a polymer particle reagent, having the general formula ##STR1## The present invention also provides a novel carbamazepine acid compound suitable for attachment to proteins for the production of carbamazepine immunogens. The carbamazepine antigen of the present invention has the following general structure: ##STR2## where X is C=O, CH.sub.2 or SO.sub.2 ; Y is C=O, CH.sub.2, SO.sub.2 ; R is ...

A polymer or copolymer composition derived from one or more unsaturated carboxylic acids that is cross-linked and carbamazepine in conjunction with conventional materials such as fillers, excipients, and surface active agents is disclosed. Solid dosage forms of immediate and sustained release tablets containing the polymer or copolymer composition can be formed by wet granulation or wet granulation followed by blending with direct compression ingredients. The polymer or copolymer, as a controlle...

Carbamazepine, in extended release form, is useful in the treatment of patients suffering from bipolar disorder. In order to minimize the time it takes to reach efficacy, carbamazepine, in extended release form, can be administered to the patient at an initial daily dose which is then increased in daily increments until clinical efficacy is achieved.

The invention is concerned with a parenteral formulation comprising a 5H-dibenz(b,f)azepine-5-carboxamide and an aqueous-based solvent. The parenteral formulation is useful in the treatment of seizures resulting from, e.g. epileptic attack.

A labeled carbamazepine analogue is described comprising: (A) a label, of the type used in immunoassays, having an amine or sulfhydryl group such as horseradish peroxidase; (B) a carbamazepine nucleus; and (C) a linking chain linking the carboxamide group of the carbamazepine nucleus to the label, said linking chain having about 4 to about 40 atoms consisting of: (1) C.sub.2 to C.sub.6 alkylene groups; and (2) 5 to 7 membered heterocyclic ring groups, each group being joined into the linking gro...

An immunoassay method and analytical elements for detecting carbamazepine drugs, for example, in body fluids, is described. The immunoassay method comprises: (A) contacting a liquid sample, containing carbamazepine, with a labeled carbamazepine analogue in the presence of antibodies for carbamazepine under conditions that promote the formation of carbamazepine/antibody immunocomplexes; and (B) determining the quantity of the drug in the liquid by measuring bound or unbound labeled drug analogue;...

The invention is concerned with a parenteral formulation comprising a 5H-dibenz(b,f)azepine-5-carboxamide and an aqueous-based solvent. The parenteral formulation is useful in the treatment of seizures resulting from, e.g. epileptic attack.

An oral administration carbamazepine medicament with a retarded active substance release is disclosed. An aqueous plasticised polymer dispersion is applied on carbamazepine crystals without causing formation of carbamazepine dihydrate. The carbamazepine crystals with their aqueous coating may be mixed with appropriate auxiliarly substances, shaped into divisible tablets or filled into capsules.

A zero-order sustained-release delivery system for delivery of carbamazepine. A matrix tablet formulations of carbamazepine comprising hydrophilic polymer gel which inhibits transformation of carbamazepine into carbamazepine dihydrate by causing morphologic changes of carbamazepine crystals and results in amorphous form of carbamazepine present in the polymer matrix.

This invention relates to an application of an anticonvulsant selected from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of said compounds in the preparation of drugs for the treatment of Parkinson's disease and parkinsonian syndromes.